![Johnson](https://www.adcreviews.com/wp-content/uploads/2022/08/Johnson-300x208.jpeg)
FDA approves first PsA pediatric target Stelara
On August 1, Johnson & Johnson/Janssen announced that the FDA approved an expanded indication of ustekinumab (Stelara) for the treatment of pediatric patients 6 years
On August 1, Johnson & Johnson/Janssen announced that the FDA approved an expanded indication of ustekinumab (Stelara) for the treatment of pediatric patients 6 years